文献速递胃肠外科

腹腔镜辅助全胃切除术后胃癌复发结局及预测模型

Recurrence outcome and prediction model of patients with gastric cancer underwent laparoscopic-assisted total gastrectomy: A retrospective study.
PubMed 文献 · Surgery · 2026-05-27

本研究基于811例可切除胃癌患者(训练集)和267例外部队列,回顾性分析腹腔镜辅助全胃切除术后的复发模式与预后因素。训练集5年实际总生存率62.5%,无复发生存率60.3%,40.0%患者复发,以远处转移为主(61.4%)。术后第12个月为区分早期与晚期复发的最佳界值(P=.011),基于pT、pN、CA72-4、CA199、CA125及SII构建的早期复发预测模型优于AJCC第八版pTNM分期,外部验证一致。

要点

  • 腹腔镜辅助全胃切除术后5年实际总生存率62.5%,无复发生存率60.3%。
  • 40.0%患者出现复发,其中远处转移占61.4%。
  • 术后12个月为早期与晚期复发的最佳区分界值(P=.011)。

核心结论

  • 可切除胃癌行腹腔镜辅助全胃切除术具有较好的长期肿瘤学结局。
  • 术后12个月是区分早期与晚期复发的最佳界值。
  • 基于pT、pN、CA72-4、CA199、CA125及SII构建的早期复发预测模型优于AJCC第八版pTNM分期,外部验证结果一致。

研究设计与样本

  • 回顾性研究,训练集为福建医科大学附属协和医院811例胃癌患者,外部验证集为莆田学院附属医院267例胃癌患者。
  • 采用最小P值法评估无复发生存的最佳阈值,将患者分为早期与晚期复发队列。
  • 采用单因素及多因素Cox回归分析预后因素。

主要发现

  • 训练集5年实际总生存率为62.5%,5年实际无复发生存率为60.3%。
  • 811例中324例(40.0%)复发,远处转移比例最高(199例,61.4%)。
  • pT分期、pN分期、神经/淋巴管侵犯、术前癌胚抗原、术前免疫炎症指数(系统性免疫炎症指数)及术后辅助化疗是总生存和无复发生存的独立预后因素(均P<.05)。
  • 早期复发113例(34.9%),晚期复发211例(65.1%),最佳界值为术后第12个月(P=.011)。
  • 与早期复发相关的因素包括pT分期、pN分期、术前癌抗原72-4、癌抗原199、癌抗原125及系统性免疫炎症指数,据此构建早期复发预测模型。

关键数值与推荐

  • 早期复发预测模型的预测评价指标显著优于美国癌症联合委员会第八版pTNM分期系统,外部验证队列亦得到相同结果。

临床怎么用

  • 该早期复发预测模型可帮助临床医生为腹腔镜辅助全胃切除术患者制定更精准的治疗和随访策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In recent years, the use of laparoscopic techniques in total gastrectomy has gradually increased. Strong evidence is urgently needed to confirm the long-term oncological outcomes of laparoscopic-assisted total gastrectomy for resectable gastric cancer. METHODS: The training set contained 811 gastric cancer patients from Fujian Medical University Union Hospital, and 267 gastric cancer patients in Putian University Affiliated Hospital were used as an external validation set. A minimum P value approach was used to evaluate the optimal threshold of recurrence-free survival to divide the patients into early and late recurrence cohorts based on the length of the postrecurrence survival. RESULTS: The training set had a 5-year actual overall survival rate of 62.5% and a 5-year actual recurrence-free survival rate of 60.3%. Of the 811 patients, 324 (40.0%) experienced recurrence, with the highest percentage of distant metastases (n = 199; 61.4%). Univariate and multivariate Cox regression analyses showed that pT stage, pN stage, nerve/lymphatic invasion, preoperative carcinoembryonic antigen, preoperative immunoinflammatory index (systemic immune-inflammatory index), and postoperative adjuvant chemotherapy were independent prognostic factors associated with overall survival and recurrence-free survival (all P < .05). The optimal cutoff time for distinguishing between early recurrence (n = 113; 34.9%) and late recurrence (n = 211; 65.1%) was the 12th postoperative month (P = .011). Factors associated with early recurrence included pT stage, pN stage, preoperative cancer antigen 72-4, cancer antigen 199, cancer antigen 125, and systemic immune-inflammatory index, based on which we constructed an early recurrence prediction model. The predictive evaluation indices of this model were significantly better than those of the American Joint Committee on Cancer Eighth Edition pTNM staging system; these results were also found in the external validation cohort. CONCLUSION: In this retrospective analysis, we found that laparoscopic-assisted total gastrectomy in patients with resectable gastric cancer had good long-term oncological outcomes, with an optimal cutoff time of 12 months postoperatively for early recurrence and late recurrence after laparoscopic-assisted total gastrectomy. The early recurrence prediction model constructed for patients with laparoscopic-assisted total gastrectomy may inform clinicians to develop more precise treatment and follow-up strategies.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Qiu TY, Zhong Q, Wu D, et al. Recurrence outcome and prediction model of patients with gastric cancer underwent laparoscopic-assisted total gastrectomy: A retrospective study. Surgery. 2026. PMID: 42335727. doi:10.1016/j.surg.2026.110347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。